Revolution Medicines, Inc. Quarterly Operating Income (Loss) in USD from Q1 2019 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Revolution Medicines, Inc. quarterly/annual Operating Income (Loss) history and growth rate from Q1 2019 to Q2 2024.
  • Revolution Medicines, Inc. Operating Income (Loss) for the quarter ending June 30, 2024 was -$157M, a 44% decline year-over-year.
  • Revolution Medicines, Inc. Operating Income (Loss) for the twelve months ending June 30, 2024 was -$601M, a 86.5% decline year-over-year.
  • Revolution Medicines, Inc. annual Operating Income (Loss) for 2023 was -$487M, a 88.6% decline from 2022.
  • Revolution Medicines, Inc. annual Operating Income (Loss) for 2022 was -$258M, a 37.4% decline from 2021.
  • Revolution Medicines, Inc. annual Operating Income (Loss) for 2021 was -$188M, a 69.8% decline from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2024 -$601M -$157M -$47.8M -44% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-07
Q1 2024 -$553M -$141M -$65.7M -87.4% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-08
Q4 2023 -$487M -$180M -$118M -192% Oct 1, 2023 Dec 31, 2023 10-K 2024-02-26
Q3 2023 -$369M -$123M -$46.7M -61% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-06
Q2 2023 -$322M -$109M -$46.7M -75.2% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-07
Q1 2023 -$275M -$75.2M -$17.2M -29.7% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-08
Q4 2022 -$258M -$61.7M -$8.8M -16.6% Oct 1, 2022 Dec 31, 2022 10-K 2024-02-26
Q3 2022 -$249M -$76.5M -$23.4M -44% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-06
Q2 2022 -$226M -$62.1M -$17.6M -39.4% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-08
Q1 2022 -$209M -$57.9M -$20.6M -55% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-08
Q4 2021 -$188M -$52.9M -$18.8M -55.3% Oct 1, 2021 Dec 31, 2021 10-K 2024-02-26
Q3 2021 -$169M -$53.2M -$25.6M -93% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-07
Q2 2021 -$144M -$44.5M -$16.6M -59.1% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-09
Q1 2021 -$127M -$37.4M -$16.3M -77.4% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-09
Q4 2020 -$111M -$34.1M -$14.5M -74.2% Oct 1, 2020 Dec 31, 2020 10-K 2023-02-27
Q3 2020 -$96.2M -$27.6M -$14M -103% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-10
Q2 2020 -$82.2M -$28M -$17.4M -165% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-11
Q1 2020 -$64.8M -$21.1M -$10.6M -102% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-10
Q4 2019 -$54.1M -$19.6M Oct 1, 2019 Dec 31, 2019 10-K 2022-02-28
Q3 2019 -$13.6M Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-12
Q2 2019 -$10.6M Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-10
Q1 2019 -$10.4M Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-14
* An asterisk sign (*) next to the value indicates that the value is likely invalid.